Al-Mufti Fawaz, Kamal Naveed, Damodara Nitesh, Nuoman Rolla, Gupta Raghav, Alotaibi Naif M, Alkanaq Ahmed, El-Ghanem Mohammad, Keller Irwin A, Schonfeld Steven, Gupta Gaurav, Roychowdhury Sudipta
Department of Neurology and Neurosurgery, Westchester Medical Center at New York Medical College, Valhalla, New York, USA; Department of Neurology, Rutgers University, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Department of Neurosurgery, Rutgers University, New Jersey Medical School, Newark, New Jersey, USA.
Department of Neurosurgery, Rutgers University, New Jersey Medical School, Newark, New Jersey, USA.
World Neurosurg. 2019 Jan;121:51-58. doi: 10.1016/j.wneu.2018.09.153. Epub 2018 Sep 27.
Intracranial arterial dissection (IAD) is a rare cerebrovascular disease that is likely underdiagnosed because of the inherent difficulty of visualizing the subtle radiographic signs of the pathologic small intracranial arteries. No widespread consensus exists on the treatment of IAD, and thus it is often managed empirically because of the absence of major randomized controlled trials. In this study, we conducted a systematic review to evaluate the management and treatment options for IAD.
We performed a systematic review in accordance with the PRISMA guidelines using the following databases: MEDLINE (PubMed) and Cochrane Library. Included studies were limited to human patients with dissections in intracranial vessels only.
A total of 82 studies were included in this systematic review. The most common complications of IAD were cerebral infarction and subarachnoid hemorrhage, and thus, patients with IAD can be subdivided into those presenting with either ischemia or hemorrhage, respectively. Those with ischemia were predominantly managed with antiplatelet therapy, whereas patients presenting with hemorrhage often were amenable to treatment with endovascular techniques.
Given these findings, clinicians should prescribe antiplatelet therapy for patients with IAD presenting with ischemia and consider endovascular treatment for those presenting with hemorrhage. However, further investigation is required given the heterogeneity of methods and reporting outcomes in the investigated studies.
颅内动脉夹层(IAD)是一种罕见的脑血管疾病,由于难以观察到颅内小动脉病变的细微影像学征象,其可能存在诊断不足的情况。对于IAD的治疗尚无广泛共识,因此由于缺乏大型随机对照试验,该病的治疗往往是经验性的。在本研究中,我们进行了一项系统评价,以评估IAD的管理和治疗选择。
我们按照PRISMA指南,使用以下数据库进行了系统评价:MEDLINE(PubMed)和Cochrane图书馆。纳入的研究仅限于仅颅内血管发生夹层的人类患者。
本系统评价共纳入82项研究。IAD最常见的并发症是脑梗死和蛛网膜下腔出血,因此,IAD患者可分别细分为出现缺血或出血的患者。缺血性患者主要采用抗血小板治疗,而出血性患者通常适合采用血管内技术治疗。
基于这些发现,临床医生应为出现缺血的IAD患者开具抗血小板治疗药物,并考虑为出现出血的患者进行血管内治疗。然而,鉴于所研究的研究方法和报告结果的异质性,仍需要进一步研究。